Willingdon Wealth Management’s NovoCure NVCR Stock Holding History

Willingdon Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-5	Closed	–	–	493
2019 Q3	$0	Buy	+5	New	+$400	﹤0.01%	530

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Willingdon Wealth Management's NVCR Position: Q4 2019 in Review

Willingdon Wealth Management sold out of NovoCure (NVCR) in Q4 2019, closing a stake of 5 shares.

Willingdon Wealth Management first reported a position in NVCR in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 262 funds tracked by Wall St. Rank hold NVCR as of Q4 2019.

Willingdon Wealth Management reported no remaining NovoCure position as of Q4 2019 after selling out during the quarter.
Willingdon Wealth Management sold 5 NovoCure shares in Q4 2019.
Willingdon Wealth Management first reported a position in NovoCure in Q3 2019 and held it in 1 quarter.
Willingdon Wealth Management's NovoCure position peaked at $0 in Q3 2019.
262 funds tracked by Wall St. Rank held NovoCure as of Q4 2019.

Based on Willingdon Wealth Management's 13F filing for Q4 2019, filed 10 Feb 2020.